Galectin-1 pulls the strings on VEGFR2

Pamela Stanley

doi:10.1016/j.cell.2014.01.059

Galectin-1 pulls the strings on VEGFR2

Pamela Stanley

Cell Biology

Research output: Contribution to journal › Short survey › peer-review

18 Scopus citations

Abstract

Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but development of resistance in patients is common. In this issue of Cell, Croci et al. identify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.

Original language	English (US)
Pages (from-to)	625-626
Number of pages	2
Journal	Cell
Volume	156
Issue number	4
DOIs	https://doi.org/10.1016/j.cell.2014.01.059
State	Published - Feb 13 2014

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cell.2014.01.059

Cite this

@article{56f15a92f94c4e399ddce0bce7614a4c,

title = "Galectin-1 pulls the strings on VEGFR2",

abstract = "Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but development of resistance in patients is common. In this issue of Cell, Croci et al. identify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.",

author = "Pamela Stanley",

year = "2014",

month = feb,

day = "13",

doi = "10.1016/j.cell.2014.01.059",

language = "English (US)",

volume = "156",

pages = "625--626",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - Galectin-1 pulls the strings on VEGFR2

AU - Stanley, Pamela

PY - 2014/2/13

Y1 - 2014/2/13

N2 - Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but development of resistance in patients is common. In this issue of Cell, Croci et al. identify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.

AB - Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but development of resistance in patients is common. In this issue of Cell, Croci et al. identify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84894156655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894156655&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2014.01.059

DO - 10.1016/j.cell.2014.01.059

M3 - Short survey

C2 - 24529367

AN - SCOPUS:84894156655

SN - 0092-8674

VL - 156

SP - 625

EP - 626

JO - Cell

JF - Cell

IS - 4

ER -

Galectin-1 pulls the strings on VEGFR2

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this